Based on an analysis of withdrawn drugs that gained approval through the FDA's fast-track program, Columbia researchers argue that such programs have positively contributed to drug development.
Kevin L. Gardner, MD, PhD, has been named senior vice chair of the Department of Pathology and Cell Biology and professor of pathology and cell biology.